Blood Markers for Predicting Clots in Myeloproliferative Neoplasms
Studies whether extra blood sampling can predict clots in adults with myeloproliferative neoplasms.
Plain-language title generated from the registry record
Registry title: Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Key facts
- Where
- Angers, Bayonne, Bordeaux, Brest, Créteil, La Roche-sur-Yon, Le Kremlin-Bicêtre, Libourne, Limoges, Morlaix, Nantes, Paris, and Roubaix, FranceSee the 15 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent diagnosis of polycythemia vera, essential thrombocythemia or pre-myelofibrosis who carry the JAK2V617F mutation and have a high risk of blood clots.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Polycythemia vera, essential thrombocythemia or pre-myelofibrosis, diagnosed within the last 12 months, with a high risk of thrombosis (age over 60 years or a prior thrombotic event)
- Earlier treatment
- People under heparin treatment at inclusion cannot join.
- Biomarker or test result
- JAK2V617F mutation with an allelic burden greater than 1%
Main reasons for not taking part
- Severe liver or kidney problems (creatinine clearance <30ml/min)
- Under legal protection (guardianship or curatorship)
- Under heparin treatment at inclusion
Read by machine on 9 November 2026.
Where in France
- CHU d'Angers - Service des Maladies du sangAngers, FranceNot yet recruiting
- CH DE LA COTE BASQUE - Service HématologieBayonne, FranceNot yet recruiting
- CHU de Bordeaux, service Hématologie BiologiqueBordeaux, FranceNot yet recruiting
- CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaireBordeaux, FranceNot yet recruiting
- CHU de Brest, Service Hématologie et Hémostase CliniqueBrest, FranceNot yet recruiting
- APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie CellulaireCréteil, FranceNot yet recruiting
- CHD de Vendée, Service Onco-hématologieLa Roche-sur-Yon, FranceNot yet recruiting
- APHP-Hôpital Bicêtre, Service Hématologie Clinique AmbulatoireLe Kremlin-Bicêtre, FranceNot yet recruiting
- CH de Libourne, Service HématologieLibourne, FranceTaking people
- CHU de Limoges, Service Hématologie Clinique et de Thérapie CellulaireLimoges, FranceNot yet recruiting
- CH des Pays de Morlaix, Service Onco-HématologieMorlaix, FranceNot yet recruiting
- CHU de Nantes, Service Hématologie CliniqueNantes, FranceNot yet recruiting
- Hôpital Privé du Confluent, Service HématologieNantes, FranceNot yet recruiting
- APHO-Hôpital Saint-Louis, Centre d'Investigations CliniquesParis, FranceNot yet recruiting
- CH de Roubaix, Service HématologieRoubaix, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT07119970
- Record updated
- 13 January 2026
- Original description
Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.Read full original descriptionShow less
Prospective Study for the Evaluation of the Prognostic Value of NETosis Markers to Predict Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation (AVATARE)
Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.
Inclusion: Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF); JAK2V617F mutation with an allelic burden greater than 1%; High risk of thrombosis (age over 60 years or prior thrombotic event); Diagnosis of MPN within the last 12 months; Enrollment in the AVAJAK clinical trial and the FIMBANK biobank; Affiliation with social security; Signed informed consent.
Exclusion: Severe hepatic or renal insufficiency (Creatinine clearance <30ml/min); Patients under legal protection (guardianship or curatorship); Patients under heparin treatment at inclusion.